Cargando…

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment

PURPOSE: To evaluate the efficacy and safety of 0.05% epinastine and 0.1% olopatadine eye drop preparations as seasonal and preseasonal treatments in patients with seasonal allergic conjunctivitis (SAC). SUBJECTS AND METHODS: This was a prospective, randomized, case-control study involving two insti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mizoguchi, Takanori, Ozaki, Mineo, Ogino, Nobuchika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627751/ https://www.ncbi.nlm.nih.gov/pubmed/29026285 http://dx.doi.org/10.2147/OPTH.S141279

Ejemplares similares

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study
por: Liu, Rui‐fen, et al.
Publicado: (2016)

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
por: Epstein, Arthur B, et al.
Publicado: (2009)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2011)

Efficacy of Olopatadine versus Epinastine for Treating Allergic Conjunctivitis Caused by Japanese Cedar Pollen: A Double-Blind Randomized Controlled Trial
por: Fukushima, Atsuki, et al.
Publicado: (2014)

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
por: Dudeja, Lakshey, et al.
Publicado: (2019)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

Retrospective Review on the Use of Topical Cyclosporin A 0.05% for Paediatric Allergic Conjunctivitis in Hong Kong Chinese
por: Wu, Macy M. S., et al.
Publicado: (2014)

p < 0.05, < 0.01, < 0.001, < 0.0001, < 0.00001, < 0.000001, or < 0.0000001 …
por: Zhu, Weimo
Publicado: (2016)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2012)

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
por: Uchio, Eiichi
Publicado: (2008)

Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial
por: Chen, Minjie, et al.
Publicado: (2022)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin, Eugene, et al.
Publicado: (2017)

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
por: Ayyappanavar, Shruti, et al.
Publicado: (2021)

Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis
por: Patel, Dharmistha, et al.
Publicado: (2018)

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
por: Torkildsen, Gail, et al.
Publicado: (2015)

Comparison of topical clobetasol propionate 0.05% and topical tacrolimus 0.1% in the treatment of cutaneous lichen planus
por: Özkur, Ezgi, et al.
Publicado: (2020)

Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
por: McLaurin, Eugene B., et al.
Publicado: (2014)

Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis study
por: Li, Shiyu, et al.
Publicado: (2023)

Comparison of the safety and efficacy of topical Tacrolimus (0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis
por: Bhargava, Rahul, et al.
Publicado: (2019)

Origin of colossal dielectric permittivity of rutile Ti(0.9)In(0.05)Nb(0.05)O(2): single crystal and polycrystalline
por: Song, Yongli, et al.
Publicado: (2016)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Combination of 0.05% Azelastine and 0.1% Tacrolimus Eye Drops in Children With Vernal Keratoconjunctivitis: A Prospective Study
por: Chen, Minjie, et al.
Publicado: (2021)

Analgesia epidural durante el trabajo de parto con ropivacaína al 0.1%, 0.075% y 0.05%
por: Colmenares Sánchez, María del Pilar
Publicado: (2002)

Peripheral iris thickness and association with iridotrabecular contact after laser peripheral iridotomy in patients with primary angle-closure and primary angle-closure glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2014)

Plateau iris in Japanese patients with primary angle closure and primary angle closure glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2015)

A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye
por: Park, Yuli, et al.
Publicado: (2017)

Efficacy of 0.05% Chlorhexidine and 0.05% Cetylpyridinium Chloride Mouthwash to Eliminate Living Bacteria on In Situ Collected Biofilms: An In Vitro Study
por: Becker, Kathrin, et al.
Publicado: (2021)

Are Only p-Values Less Than 0.05 Significant? A p-Value Greater Than 0.05 Is Also Significant!
por: Kwak, Sanggyu
Publicado: (2023)

Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis
por: Dehar, Navdeep, et al.
Publicado: (2012)

Unexpected Cardiovascular Oscillations at 0.1 Hz During Slow Speech Guided Breathing (OM Chanting) at 0.05 Hz
por: Hotho, Gerard, et al.
Publicado: (2022)

Interplay of piezoresponse and magnetic behavior in Bi(0.9)A(0.1)FeO(2.95) (A = Ba, Ca) and Bi(0.9)Ba(0.05)Ca(0.05)FeO(2.95) co-doped ceramics
por: Mangamma, G., et al.
Publicado: (2022)

0.05 - 100 MHz 4 W amplifier
por: Paoluzzi, M
Publicado: (1997)

Halometasone monohydrate (0.05%) in occupational contact dermatitis
por: Maiti, Rituparna, et al.
Publicado: (2016)

The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: Protocol for a systematic review
por: Zi, Yingxin, et al.
Publicado: (2020)

Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: a pilot study
por: Joachimsen, Lutz, et al.
Publicado: (2021)

Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen
por: Chan, Yuan-Hsi, et al.
Publicado: (2023)

Electrochemical properties of La(0.5)Sr(0.5)Fe(0.95)Mo(0.05)O(3−δ) as cathode materials for IT-SOEC
por: Hou, Yunting, et al.
Publicado: (2021)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Nakakura, Shunsuke, et al.
Publicado: (2012)

A Prospective Study of Cyclosporine A 0.1% Combined with Loteprednol 0.2% vs Cyclosporine A 0.05% Alone in the Treatment of Dry Eye
por: Hovanesian, John, et al.
Publicado: (2023)

Tuning of the Structure and Magnetocaloric Effect of Mn(1−x)Zr(x)CoGe Alloys (Where x = 0.03, 0.05, 0.07, and 0.1)
por: Kutynia, Karolina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gqf8f3a5dctjvoend13uoci01u